Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-05. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001193125-26-335373
acquired disposedD
codeS
direct or indirectD
form4
is derivativefalse
issuer nameMBX Biosciences, Inc.
labelOpen market sale
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001193125-26-335373",
"acquired_disposed": "D",
"code": "S",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "MBX Biosciences, Inc.",
"label": "Open market sale",
"person_name": "Azoulay Salomon",
"price": 65.77,
"role": "Chief Medical Officer",
"security": "Common Stock",
"shares": 370,
"shares_owned_after": 14399,
"source_path": "edgar/data/2030246/0001193125-26-335373.txt",
"ticker": "MBX",
"transaction_date": "2026-08-04",
"value": 24334.9
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.